National procurement with the expansion of the official launch: the scope of procurement is still the first 25 varieties
The expansion of national procurement with quantity officially started. September 1, Shanghai Sunshine Pharmaceutical Procurement Network announced the "Alliance Area Drug Centralized Procurement Document", which shows that this collection expansion will be pushed in 25 areas such as Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Jiangsu and Zhejiang, with the exception of 4+7 cities in the Alliance area. Involving the first batch of pilot atorvastatin oral normal release dosage form and other 25 winning varieties.
Unlike the first batch of pilot drug varieties where only one drug company won the bid, this time the same variety can be multiple winning bids, and the corresponding procurement volume also varies. The document shows that the actual selected enterprise is 1, the agreed procurement volume for the first year agreed procurement volume of 50% of the base calculation; the actual selected enterprise is 2, the agreed procurement volume for the first year agreed procurement volume of 60% of the base calculation; the actual selected enterprise is 3, the agreed procurement volume for the first year agreed procurement volume of 70% of the base calculation.
Looking for chemical products? Let suppliers reach out to you!
2026-06-20
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Biocytogen announces the launch of the 'Nano 100 Project' to develop fully human therapeutic nanobodies against 100+ targets
-
Wantai Biotech 20-valent pneumonia vaccine started clinical trials, how far is domestic substitution?
-
Yiming Cell 'Suspension 293XS Cell Bank' completed DMF filing with the US FDA
-
The phase III clinical study of Junshi Biologics in combination with teripulimab in the treatment of advanced triple-negative breast cancer reached the primary endpoint
-
The next bombshell: 'PD-1 + ADC', Kelun, Hengrui are going to win numbness?
-
L-Rotator Biotech completed its pre-A financing and continued to increase its investment in the CGT field
-
Hainan to promote drug import facilitation
-
Enable the 'export of EU APIcertification documents' and 'pharmaceutical export salescertificate' electronic proof
-
China to focus on building quality and efficient TCM service system in next five years
Recommend Reading
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
2026 China Acrylonitrile Market "Continuation and Resolution of the Darkest Moment"
-
End-of-Month Maleic Anhydride Market Trends Primarily Consolidating
-
Polyethylene Supply and Demand Imbalance in 2025, Excess Situation Unchanged in 2026
-
China's Urea Market Fluctuates (11.21-11.28)
-
Natural Rubber Prices Fluctuated Downward in 2025, Bottom Support Exists in 2026 with a Slight Shift Upward in Price Focus